
# WE WILL FIND A CURE TOGETHER

(VIRTUALLY IF NECESSARY!)

# 2020 ANNUAL REPORT





# TABLE OF CONTENTS

LETTER FROM THE CO-FOUNDERS	3
WHAT WE DO AND WHY IT MATTERS	4
2020 DTRF KEY EVENTS AND ACHIEVEMENTS	5
DTRF-FUNDED 2020 GRANTS	8
FINANCIALS	8
DTRF 2020 SIGNATURE EVENTS	9
OUR TEAM	15

# A LETTER FROM THE CO-FOUNDERS



Marlene Portnoy, Executive Director/Co-founder and Jeanne Whiting, President/Co-founder

Dear friends,

We thank everyone who has helped make this landmark year of 2020 a year of progress for DTRF. September of 2020 marked the 15th anniversary of DTRF's founding! Fifteen years is a major milestone. While half of rare diseases don't have a foundation or a research support group (source: Global Genes), we are grateful for the continued support that enables us to still be here fighting for you.

The year 2020 will go down in history as one of the most challenging for non-profits due to the worldwide COVID-19 pandemic. However, we are grateful for advisors, staff and volunteers who kept DTRF moving forward and thriving despite the year's challenges.

We pivoted to hold all of our meetings and September annual events virtually, and nearly tripled our participation in research meetings. Virtual communication and conferences have in many ways fostered even more effective collaboration and worldwide participation in our important initiatives like the DTRF Virtual Tumor Board and the annual DTRF International Research Workshop.

We've been gratified to hold interactive patient meetings and networking events to support and sustain our patient and caregiver community from all corners of the planet. And our community rallied around our Desmoid Tumor Awareness Month and Virtual Challenge fundraising event to keep the research funding going.

As always, our mission continues to be funding research toward a cure, and advocating for patients. We are grateful for the virtual technology that has brought us together this year, and we look forward to in-person meetings in the future.

Celebrating the 15th anniversary of our founding has been a poignant milestone. DTRF is grateful every day for our passionate community that has rallied to support us, and for our scientific and medical advisors and researchers. And we deeply appreciate our generous donors and fundraisers who have stayed with us for the long haul, and the new ones who join in the cause every year! Thank you all!

Sincerely,

DTRF Co-founders

eanne White

Jeanne Whiting President and Co-founder

plasten Port

Marlene Portnoy Executive Director and Co-founder





# WHAT WE DO AND WHY IT MATTERS

# **OUR MISSION**

Founded in 2005, the mission of The Desmoid Tumor Research Foundation is to aggressively fund research to accelerate the development of improved therapies, and ultimately find a cure for desmoid tumors. We collaborate with dedicated researchers and clinicians worldwide to improve the lives of patients through education, awareness and support. The founders have a deep sense of urgency in this cause motivated by a personal connection to the disease. We press forward to fund cutting-edge research that will develop new effective therapies for desmoid tumors, leading to the ultimate goal, a cure!

**RESEARCH FUNDING.** DTRF is the only foundation in the country solely dedicated to funding desmoid tumor research and finding a cure for this rare disease. The funding of cutting-edge collaborative research continues to be our priority. We fund research projects at the world's top sarcoma cancer research centers in both basic science and clinical trials. DTRF-funded research seeks to determine what goes wrong in cells to generate these tumors, what medical and surgical options work best, and what existing drugs or potential new drugs could provide effective treatments.

**DTRF facilitates collaboration** between researchers from different institutions to expedite the development of a cure. DTRF-funded research has made significant advancements in our understanding of the disease. Discoveries made through desmoid tumor research can also potentially have a significant impact on many other more common cancers such as breast, colon, ovarian and other cancers.

**EDUCATION AND COLLABORATION.** DTRF has established a very successful annual fall Patient Meeting which brings patients, physicians and researchers together for education, support and collaboration. In connection with the Patient Meeting, we hold the annual DTRF International Desmoid Tumor Research Workshop. This event brings together a diverse group of scientists from around the world including the brightest minds in desmoid tumor research, human genetics, drug development and related fields. The Workshop facilitates an enthusiastic and collegial atmosphere as researchers across disciplines and institutions collaborate around the shared goal of improving treatments for desmoid tumor patients, establishing research priorities and moving the field forward toward a cure. In addition, our website is a clearinghouse of information on desmoid tumors and published desmoid tumor research, reaching patients, physicians and researchers around the globe.

**PATIENT SUPPORT.** Patients are not fighting this disease alone. Our website provides information and helps direct patients to other sources for information, support and resources. Our annual Patient Meeting provides a supportive environment for patient interaction and informative lectures by clinicians and researchers. Most of all, we seek to support patients by giving them hope through funding research for a cure. Our fundraising events around the country promote awareness and give patients and their families and friends a healing way to make a difference as proactive advocates for a cure.

# WE KNOW THAT OUR GOAL OF A CURE IS WITHIN REACH... AND WE WILL GET THERE TOGETHER.

# 2020 KEY EVENTS AND ACHIEVEMENTS

# **JANUARY 2020**

**DTRF's Partnership with The Broad.** We continued our partnership with the Broad Institute of MIT & Harvard. **Their Rare Cancer Dependency Map Initiative has created patient models from living tissue and is using CRISPR/drug data** to help researchers map the best desmoid tumor drug targets. We're grateful to our patients who donated tissue which has been used to create cell lines that are ready for CRISPR technology. Learn more about The Broad's Rare Cancer Dependency Map Initiative, which includes desmoid tumors.

# FEBRUARY 2020

**The first of its kind Global Consensus Paper was published in the European Journal of Cancer.** Supported by DTRF, this project came to fruition thanks to the hard work and collaboration of an international group of physicians and scientists, as well as patient advocates. By evaluating existing evidence from prior scientific publications, and incorporating the input of desmoid tumor experts worldwide, the paper is the first evidence-based consensus of its kind on the treatment of desmoid tumors. It answers critical questions regarding approach to treatment options, types of treatment, and pain management. There are varying treatments used for desmoid tumors, and access to medical therapies and expertise varies greatly by country. DTRF has made it a priority to improve this situation by making this collaborative paper available to physicians and patients worldwide. This paper is, in part, the result of a 2018 DTRF grant entitled *An evidence-based consensus on the treatment of desmoids*.

# **APRIL 2020**

**DTRF research funding and patient registry progress.** This year, "rare cancers" was one of three new areas of medical research added to the Congressionally Directed Medical Research Programs (CDMRP), a Department of Defense (DoD) research funding program. Representing DTRF, Dr. Kelly Mercier presented at the CDMRP Stakeholders' meeting, which aimed to capture the important aspects that are needed to be considered in the rare cancer funding mechanism. The stakeholders included participants from the National Institutes of Health (NIH), the U.S. Food and Drug Administration (FDA), and patient advocacy groups who participate and fund rare cancer research. Dr. Mercier described the progress that DTRF has made in funding research in desmoid tumors and characterized the types of research (basic, translational, and clinical), as well as the need for increased data sharing and oversight.

# **MAY 2020**

**Timely Tumor Talks** During the pandemic, we continued our community networking efforts virtually with a spring "Timely Tumor Talks" event. This virtual networking opportunity allowed patients and caregivers to connect from their own homes. Desmoid patients and caregivers are not alone in their desmoid journey!

## **AUGUST 2020**

**Podcast: The Behind-the-Scenes Story of the Breakthrough Sorafenib Clinical Trial.** DTRF Co-founder, Marlene Portnoy, and DTRF Scientific Director, Dr. Mrinal Gounder of Memorial Sloan Kettering Cancer Center, recorded a conversation for the American Society of Clinical Oncology's (ASCO) Conquer Cancer Foundation's Annual "Your Stories" mini-podcast project. The conversation focused on the role of DTRF's patient advocacy in leading to the breakthrough clinical trial for sorafenib (Nexavar). <u>Listen to the podcast</u> by ASCO's ConquerCancer Foundation.

# **AUGUST 2020**

**Clinical Trial announcements** this year: **SpringWorks Therapeutics Announced Full Enrollment of Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Desmoid Tumors as follows:** "Nirogacestat has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of desmoid tumors (June 2018) and from the European Commission for the treatment of soft tissue sarcoma (September 2019). The FDA also granted Fast Track and Breakthrough Therapy Designations for the treatment of adult patients with progressive, unresectable, recurrent or refractory desmoid tumors or deep fibromatosis (November 2018 and August 2019)."

Also, Iterion Therapeutics Initiated Enrollment of Phase 2a Dose Expansion Study of Tegavivint in Patients with Desmoid Tumors. Iterion's press release explained: "The Phase 2a trial builds on a recently completed Phase 1 study that established safety and initial clinical efficacy of Tegavivint in patients with progressive desmoid tumors. It is expected to enroll up to 25 patients who will be treated with the recommended Phase 2 Dose (RP2D), which was established based on pharmacokinetic exposure levels and clinical responses in the recently completed Phase 1 study... 'We are very pleased to advance the clinical development of Tegavivint in desmoid tumors as this disease target is greatly underserved and provides an optimal indication for demonstrating the drug's safety and potential clinical utility in multiple cancer settings,' said Rahul Aras, CEO of Iterion. 'Our development plan for Tegavivint is to advance its development in desmoid tumors as a launching point for additional programs in acute myeloid leukemia, non-small cell lung cancer, and certain pediatric cancers for which nuclear β-catenin signaling has been identified as a potential therapeutic target.'''



### **SEPTEMBER 2020**

#### DTRF's 15th Anniversary!

Fifteen years ago DTRF was co-founded by Jeanne Whiting and Marlene Portnoy. They met online when Jeanne was being treated for a desmoid tumor, as was Marlene's husband. In their separate journeys they had quickly learned that the disease was very rare, there was little information available, few treatments that were only sporadically effective, no established treatment protocol, no FDA-approved treatment, and little research being done.

They decided to try to make a difference by creating a foundation in 2005. They've often referred to themselves as "two women at their kitchen tables" trying to make a difference. Fortunately, DTRF is still here and going strong 15 years after our founding! It has been a wonderful milestone to celebrate this year.

6



Swing for a Cure Event - Sept 28, 2020

#### **SEPTEMBER 2020**

DTRF's annual meetings were held virtually with great success. Keep reading for more details.

# **NOVEMBER 2020**

**Initiating a New Investigator Research Grant.** This year we initiated the Dr. Dina Lev New Investigator Memorial Research Grant named in honor of Dina Chelouche Lev, M.D., an early leader in desmoid tumor research. Dr. Lev was one of the original recipients of research support from the Desmoid Tumor Research Foundation in 2007, starting a reciprocal relationship that continued until her untimely passing in 2020 at the age of 55. The award embodies Dr. Lev's endless enthusiasm and tireless effort toward moving the science of desmoid tumors forward, as well as her commitment to the training of young surgeons and scientists interested in connective tissue tumor oncology, including desmoid disease. The Dr. Dina Lev New Investigator Memorial Research Grant is given to promising new investigators who are dedicated to advancing the science of desmoid tumors with an eye toward exerting a long-term influence in the field.

# **NOVEMBER 2020**

**The new DTRF Coordinating Center (DTRFCC).** Collaborative research has always been the priority at the heart of the Foundation. However, this initiative will take those efforts to the next level, further accelerating our journey to a cure. The DTRFCC aims to connect researchers and their data, and to promote increased purposeful collaboration across various fields of study. We're thrilled to announce that this project is now underway! Kelly Mercier, PhD, was named as the new Chair of the DTRFCC, and a search began for a new research director to lead the center. (Maneesh Kumar, MD, PhD was named Research Director of the DTRFCC in early 2021.)



# **DTRF-FUNDED 2020 GRANTS**

NOTE: The COVID-19 pandemic interrupted or delayed research at many institutions, impacting our grant applications, awards and renewals in 2020. However, the following grants were made.

# **MULTI-YEAR GRANTS CONTINUING IN 2020**

- » Jesse Boehm, PhD, Associate Director of the Cancer Program, Director of the Cancer Cell Line Factory, Principal Investigator in the Cancer Model Development Center, Institute Scientist, The Broad Institute of MIT and Harvard, "Using genome-scale CRISPR screening to create a Desmoid Tumor Dependency Map," Year 2 of 3.
- » Kris Vleminckx, PhD, Ghent University, "Identifying targets for therapy in a novel genetic Xenopus model for desmoid tumor formation," Year 2 of 2.

# **FINANCIALS**

The Desmoid Tumor Research Foundation depends on the generosity of donors to carry out its mission and we value every dollar received. DTRF is a 501(c)(3) tax-exempt organization and donations are tax deductible to the extent allowed by law.

# **VIEW OUR:**

- » IRS 501(c)(3) determination letter
- » 2020 IRS Form 990
- » 2020 Audited Financial Statement



# **DTRF 2020 SIGNATURE EVENTS**

# TOGETHER WE WILL VIRTUAL WEEKEND, SEPT. 25-27, 2020

For over a decade, we've prioritized our annual fall weekend in Philadelphia as the time when our community comes together faceto-face. With the COVID-19 pandemic we pivoted to virtual Zoom meetings, seeing an opportunity to grow and to reach more people than ever.

This year's **Together We Will Virtual Weekend** convened our largest number to date of medical professionals, patients and caregivers, and fundraisers for a full weekend of setting research priorities, learning, networking and connecting.

# **TOGETHER WE WILL... ADVANCE RESEARCH**

#### Seventh International DTRF Desmoid Tumor Research Workshop, Sept. 25, 2020

Every year, DTRF holds an annual research workshop to facilitate international scientific education and collaboration. In the 2020 virtual format, we were pleased to have 190 registered attendees from 72 institutions in 32 different countries!

Participants included those involved in desmoid tumor research, human genetics, drug development and related fields. In addition to short scientific presentations, significant time was dedicated to discussions around the important questions: What are the gaps in the science that we need to address next? How can we collaborate to move the science forward most efficiently?

#### Institutions and Industry represented at the Workshop included:

All India Institute of Medical Sciences (India) Angel H. Roffo Institute of Oncology, Univ of Buenos Aires, Argentina Anwer Khan Modern Medical College, Bangladesh Aretaieio University Hospital, Athens, Greece **Ayala Pharmaceuticals** Bilaspur University, India **Boston University** Cancer Institute of Iran Children's Mercy Hospital **Children's Hospital Los Angeles** Chris O'Brien Lifehouse, Australia Contactgroep Desmoid, Netherlands Dana Farber Cancer Institute Dmitry Rogachev Nat'l Medical Research Center of Pediatric Hematology, Oncology, Immunology **Duke University** Emory University Erasmus Medical Center, Rotterdam the Netherlands Fondazione IRCCS Istituto Tumori di Milano, Italy Ghent University, Belgium Herlev Hospital, Denmark Hôpital Maisonneuve-Rosemont, Canada Hospital de Clinicas, Paraguay Huntsman Cancer Institute, University of Utah **IHOPe-Leon Berard Center, France** Institute of Cancer Research, United Kingdom Instituto Nacional de Cancerologia, Mexico Istituto Tumori Milano, Italy Johns Hopkins Hospital Kyushu University, Japan LaserCure, India London Sarcoma Service, University College, United Kingdom Louisiana State University **Maine Medical Center** Mannheim University Medical Center, University of Heidelberg, Germany The Mayo Clinic MD Anderson Cancer Center

Memorial Sloan Kettering Cancer Center Military Hospital of Tunis, Tunisia Moffitt Cancer Center Mount Sinai Hospital, University of Toronto, Canada N.N. Priorov Institute of Traumotology and Orthopedics, Russia Nagoya University, Japan Nat'l Institutes of Environmental Health Sciences National Cancer Center, Japan National Cancer Institute Nemours Children's Specialty Care **Oxford University Hospitals** Peking University, China Peter MacCallum Cancer Center Philippine General Hospital, Philippines Rabin Medical Center, Israel University of Iowa University of Miami, Sylvester Comprehensive Cancer Center Rede DO'R, Brazil **Roswell Park Cancer Institute** Royal Marsden Hospital, United Kingdom Servier Pharmaceuticals Sheba Medical Center, Israel SOS Desmoide, France SpringWorks Therapeutics St. Stephen's Hospital Stanford University School of Medicine The Broad Institute of MIT and Harvard The Chinese University of Hong Kong The Ohio State University University Hospital, Zurich, Switzerland University of Arkansas for Medical Sciences University of California- San Diego, Rady Children's Hospital University of Colorado- Anschutz Campus University of Florida **Utah Cancer Specialists** Vanderbilt University Medical Center



Together We Will Virtual Weekend, Sept. 25-27, 2020

# THE FOLLOWING PRESENTATIONS WERE GIVEN AT THE 2020 RESEARCH WORKSHOP:

**Benjamin Alman, MD**, Professor & Chair, Orthopedic Surgery, Duke University, *"Mouse models in desmoid tumors."* 

Jesse Boehm, PhD, Scientific Director of the Cancer Dependency Map, Associate Director of the Cancer Program, Director of the Broad Cancer Model Development Center, The Broad Institute of MIT and Harvard, *"The Desmoid Tumor Dependency Map."* 

**Kris Vleminckx, PhD**, Professor of Developmental Biology, Ghent University, *"Identifying and characterizing dependency factors in a genetic Xenopus tropicalis desmoid tumor model."* 

**Paul Huang, PhD**, Head, Molecular and Systems Oncology Laboratory, Division of Molecular Pathology, The Institute of Cancer Research, *"Deconstructing the desmoid tumour matrisome."* 

**Kelly Mercier, PhD**, Adjunct Associate, Duke University; Medical Science Liaison, Jazz Pharmaceuticals, Inc., "Stable isotope resolved metabolomics to interrogate the interactions between stroma and desmoid tumors."

**Joanna Przybyl, PhD**, Instructor, Department of Pathology, Stanford University, "Genome-wide DNA methylation profiling of desmoid tumors."

**Gerlinde Wernig, MD**, Assistant Professor, Department of Pathology, and Tristan Lerbs, PhD, Post doctoral Researcher, Stanford University School of Medicine, *"Jun and its Connections with Wnt and Notch."* 

**Anne-Rose W Schut, MD**, PhD candidate, Surgical Oncology, Erasmus Medical Center Cancer Institute, *"The mechanism of Sorafenib in desmoid-type fibromatosis."*  Javier Martin Broto, MD, PhD, Instituto de Biomedicina de Sevilla (IBIS), "Activity of taxanes in progressive or symptomatic desmoid tumors."

**Breelyn A. Wilky, MD**, Associate Professor, University of Colorado Anschutz Medical Campus, "Association of CTNNB1 mutation subtypes with responses to systemic therapy in patients with desmoid tumors."

**Christina Kosyla**, Desmoid tumor patient and advocate.

**Sameer Rastogi, MD**, Medical Oncologist, All India Institute of Medical Sciences, "Desmoid fibromatosis management in tertiary care center in India-Lessons learned."

**Aaron Weiss, DO**, Associate Professor of Pediatrics, Maine Medical Center (Chair, DTRF Medical Advisory Board), *"The DTRF Virtual Tumor Board."* 

**Kelly Mercier, PhD**, Adjunct Associate, Duke University; Medical Science Liaison, Jazz Pharmaceuticals, Inc., *"The DTRF Natural History Study."* 

**Chen Duksin, MD**, MBA, Executive Medical Director, Ayala Pharmaceuticals, "AL102, Oral Gamma-Secretase Inhibitor for the Treatment of Patients Living with Desmoid Tumors."

**Fariba Navid, MD**, Associate Professor at the Keck School of Medicine and Medical Director of Clinical Research Support Office for the Cancer and Blood Disease Institute at Children's Hospital Los Angeles, "ARST1921: A Safety Pharmacokinetic and Efficacy Study of a y-Secretase Inhibitor, Nirogacestat (PF-03084014), in Children with Adolescents with Progressive, Unresectable Desmoid Tumors."



# **TOGETHER WE WILL.... CONNECT**

# DTRF Virtual Community Networking Event, Sept. 25, 2020

In the spirit of our previous "Speed Desmoidian-ing" in-person event, and our virtual "Timely Tumor Talks" event in the spring, this September virtual networking event provided a structured conversation allowing patients and caregivers to share their journeys and experiences. To ensure a more personal setting in our virtual Zoom environment, there were multiple breakout groups and interactive engagement tools. Kudos go to Patient Advocate and FAP survivor Dakota Fisher-Vance who imagined and moderated the event.

# **TOGETHER WE WILL... EMPOWER OURSELVES WITH INFORMATION**

#### DTRF Virtual Patient Meeting Webinars, Sept. 26, 2020

Our virtual Patient Meeting consisted of two separate one-hour webinars, focusing on topics important to the patient community. Roughly 170 community members joined us internationally. Patients submitted questions via the written Q&A as well as live after each panelist presentation.

## Our patient meeting webinars included the following presentations:

#### Webinar #1: Desmoid Tumors 101 featured topics:

- » Collaborations with patient advocacy groups by Dr. Mrinal Gounder, Memorial Sloan Kettering Cancer Center (Scientific Director, DTRF)
- » An overview of desmoid tumors by Dr. Breelyn A. Wilky, University of Colorado
- » Pediatrics by Dr. Aaron Weiss, Maine Medical Center (Chair, DTRF Medical Advisory Board)
- » Pregnancy by Dr. Chandrajit Raut, Brigham and Women's Hospital and Dana-Farber Cancer Institute

### Webinar #2: Therapies and Clinical Trials for Desmoid Tumors featured topics:

- » High Intensity Focused Ultrasound (HiFU) by Dr. Matthew Bucknor, University of California- San Francisco
- » Intra-arterial doxorubicin drug-eluting embolization (DEE) by Dr. Eldad Elnekave, Rabin Medical Center
- » Nirogacestat Phase 3 Trial by Dr. L. Mary Smith, SpringWorks Therapeutics
- » Tegavivint Phase 2a Trial by Dr. Casey Cunningham, Iterion Therapeutics

### Special thanks goes to SpringWorks Therapeutics for its generous sponsorship of the Patient Meeting.

# **TOGETHER WE WILL... FUND A CURE!**

### RFA Virtual Challenge, July - Sept., 2020

The DTRF is principally funded by grass-roots private donations raised through signature DTRF events and patient-organized fundraising events. Volunteers, including patients, caregivers and supporters, are encouraged to plan and host fundraisers around the country. We cannot accomplish our mission without this support and are always here to help!



With the pandemic, most in-person fundraisers were cancelled so we had to get creative and expand our virtual fundraising. The patient-caregiver community rallied around our **RFA Virtual Challenge**. Patients participated from all over the world, feeling connected to each other while helping us achieve our collective fundraising goal. "Challengers" were invited to create their own personal challenges, match them with a fundraising goal, document their successes and share them with the community. We were so inspired by the ideas, support and drive to achieve these goals. There were opportunities for virtual check-ins and virtual celebrations daily around personal achievements and fundraising milestones.



EVERY \$200 RAISED TO BENEFIT DTRF GETS A NEW SONG


For her RFA Virtual Challenge, Jackie recruited donors online by promising lip sync videos

## Here are just a few of the goals set by our Challengers:

- » **Bri** walked 1 mile for every \$100 she raised. She invited family and friends to join her as she walked toward her fundraising goal!
- » **Dana** hiked over 16,000 feet in elevation and wove that magical number into her fundraising ask!
- » **DeAnn** rode 2,100+ miles to Philly virtually, on her stationary bike, recruiting donors as her team members. They gave, did the mileage, and some did both!
- » Two challengers walked virtually from their home towns to Philly. **DeeDee** walked from Maryland and **Rachel** from Virginia. They asked friends and family for pledges and shared their progress and photos every few days.
- » **Jackie** created a wacky lip sync video for every \$200 she raised for DTRF. Family and friends got involved and kept her busy creating videos.
- » **Lisa** created a fundraising page for Desmoid United UK, and worked with her community to hit their fundraising goal!
- » Lynne would get a buzz cut if she reached her goal.
- » Natalie did a 5K for every \$200 she raised.
- » Jeanne and her husband Steve rowed 100,000 meters on the Great Salt Lake.

VIRTUAL CHALLENGE

20**20** 



# **OUR TEAM**

# LEADERSHIP, VOLUNTEERS AND STAFF

MARLENE PORTNOY Executive Director and Co-founder

JEANNE WHITING President and Co-founder

LYNNE HERNANDEZ Director of Events, Operations and Outreach

MRINAL GOUNDER, MD. Scientific Director Memorial Sloan Kettering Cancer Center

**AMANDA HOFFMAN** Marketing/ Media Advisor **KATE WENC** Published Research Advisor

MICHAEL HRUPEK Brand Advisor & Graphic Designer

**PHILIP GRAND** Technical Advisor

WENDY L. KAUFMAN Certified Public Accountant

#### BOARD OF DIRECTORS

MARIA CROCITTO Chief Executive Officer, Advantage Communications, LLC

NICOLE DEICHERT Sr. Human Resources Manager, Ecolab, Inc.

JOEL KORAL Financial Representative, Northwestern Mutual

JERROLD MARCH Executive Vice President, KenKen LLC

MARLENE PORTNOY Executive Director and Co-founder, DTRF

**KEVIN REILLY** Motivational Speaker and desmoid tumor survivor BARBARA ANN SELLINGER, Esq. Board of Directors, The Desmoid Tumor Research Foundation

**RACHEL SITTA** Director of Contracts, Compliance and Pricing, Cardno International Development

JEANNE WHITING President and Co-founder, DTRF

**STEVEN WHITING** Financial Markets Consultant

15

# MEDICAL ADVISORY BOARD

AARON WEISS, DO (Chair) Associate Professor of Pediatrics, Maine Medical Center

**ROBERT BENJAMIN, MD** MD, Clinical Professor, Sarcoma, MD Anderson Cancer Center

RASHMI CHUGH, MD Assistant Professor, Medical Oncology, Department of Internal Medicine, University Of Michigan Health System

PALMA DILEO, MD Consultant Medical Oncologist, London Sarcoma Service, University College London Hospitals

RICK HAAS, MD, PhD Division of Radiotherapy, Netherlands Cancer Institute

PETER HOHENBERGER, MD, PhD Professor of Surgical Oncology, University of Heidelberg

MRINAL GOUNDER, MD Associate Professor and Medical Oncologist, Memorial Sloan Kettering Cancer Center

**BERND KASPER, MD, PhD** Professor, Mannheim University Medical Center

#### ROBERT LEFKOWITZ, MD

Associate Professor, Radiology, Weill Cornell Medical College/ Memorial Sloan-Kettering Cancer Center

CHRISTIAN MEYER, MD, PhD Instructor of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

RAPHAEL POLLOCK, MD, PHD Director, Ohio State University Comprehensive Cancer Center

#### CHANDRAJIT RAUT, MD

Director, Surgical Oncology, Sarcoma, Associate Professor of Surgery, Harvard Medical School

VINOD RAVI, MD Associate Professor, Vascular Sarcomas, MD Anderson Cancer Center

SYLVIA STACCHIOTTI, MD Medical Oncologist, Fondazione IRCCS Istituto Nazionale Dei Tumori

KEILA TORRES, MD, PhD Assistant Professor, Department of Surgical Oncology, Division of Surgery, MD Anderson Cancer Center

### SCIENTIFIC ADVISORY BOARD

#### AIMEE CRAGO, MD, PhD (Chair)

Assistant Attending Surgeon, Memorial Sloan Kettering Cancer Center

#### BENJAMIN ALMAN, MD

Department Chair, Orthopedic Surgery, Duke University

### MRINAL GOUNDER, MD

Associate Professor and Medical Oncologist, Memorial Sloan Kettering Cancer Center

#### ALEXANDER LAZAR, MD, PhD

Director, Department of Pathology, The University of Texas -MD Anderson Cancer Center Selective (Soft Tissue) Pathology Fellowship Training Program

#### ROBERT MAKI, MD, PhD

Clinical Director, Sarcoma Program and Professor of Medicine at the Hospital of the University of Pennsylvania

#### KELLY MERCIER, PhD

Chair of the DTRF Coordinating Center, adjunct associate professor at Duke University and Diagnostics Regional Medical Lead for Daiichi Sankyo

#### ROEL NUSSE, PhD

Professor of Cancer Research and of Developmental Biology at Stanford University School of Medicine, Program Director of Stanford's Cancer Stem Cell Research Program, and member of Stanford's Institute for Stem Cell Biology and Regenerative Medicine

#### JEAN PATY, PhD

Vice President, Patient Centered Endpoints, IQVIA

#### MATTHEW VAN DE RIJN, MD, PhD

Professor, Department of Pathology, Stanford University Medical Center

#### BREELYN WILKY, MD

Associate Professor & Director of Sarcoma Translational Research, University of Colorado School of Medicine

"I have challenged myself to climb a cumulative 16,404 ft in elevation... and also to raise that same amount in donations for DTRF... Together, we are increasing awareness about this disease and helping others to find the cure!"

Dana L.



The Desmoid Tumor Research Foundation, Inc. P.O. Box 273 Suffern, New York 10901

FOR INFORMATION PLEASE CONTACT: Marlene Portnoy Executive Director and Co-founder marlene@dtrf.org

dtrf.org